Curie-Cancer and Servier renew partnership into ‘triple negative’ breast cancers

French privately-held drugmaker Servier has renewed its partnership with Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, to identify therapeutic targets for treating ‘triple negative’ breast cancers for a further three years.

‘Triple negative’ breast cancers account for around 15% per cent of breast cancer cases – they are particularly aggressive and can be unresponsive to the current chemotherapy regimens. Triple negative breast cancers do not express estrogen or progesterone receptors (in which case they could be treated with hormone therapy), or Her-2 receptors (which would allow for targeted therapies that bind to Her-2 receptors). The partners will share the intellectual property resulting from this work.

Encouraging initial results